Announcements Trials

Browse Landscape

Phase

Phase 2 1 Phase 1/2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1 Gastrointestinal 1 CNS 1

Conditions

Squamous Cell Carcinoma of Head and Neck 2 Polycystic Ovary Syndrome 2 Pancreatic Neoplasms 2 Melanoma 2 Head and Neck Neoplasms 2 Endometrial Neoplasms 2 Breast Neoplasms 2 Uterine Cervical Neoplasms 1 Prostatic Neoplasms 1 Prostate Cancer Recurrent 1 Ovarian Neoplasms 1 Neoplasms by Site 1 Neoplasms 1 Infertility 1 Hereditary Sensory and Autonomic Neuropathies 1 Glioma 1 Chondrosarcoma 1 Cholangiocarcinoma 1 Carcinoma, Renal Cell 1 Breast Diseases 1

Interventions

Temozolomide 26 Radiotherapy 10 Bevacizumab 10 Carboplatin 6 Irinotecan 5 pembrolizumab 4 Radiation 4 Nivolumab 4 IL13-PE38 4 temsirolimus 3 Surgical Procedures, Operative 3 Magnetic Resonance Spectroscopy 3 Immunotherapy, Adoptive 3 Erlotinib Hydrochloride 3 Aminolevulinic Acid 3 trametinib 2 olaparib 2 lutetium Lu 177 dotatate 2 fludarabine 2 dabrafenib 2 cemiplimab 2 abemaciclib 2 Vorinostat 2 Transurethral Resection of Bladder 2 Sirolimus 2 Radiotherapy, Intensity-Modulated 2 Radiosurgery 2 Imatinib Mesylate 2 Flucytosine 2 Cyclophosphamide 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Glioma × Metformin × Clear all

NCT02496741 2020-01-09

MACIST

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

Phase 1/2 Completed

CNSGastrointestinalSarcoma

Chondrosarcoma, Glioma, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡